Rituximab therapy for steroid-dependent minimal change nephrotic syndrome

Pediatr Nephrol. 2006 Nov;21(11):1698-700. doi: 10.1007/s00467-006-0228-x. Epub 2006 Aug 24.


We present a patient with steroid-sensitive but high-dose steroid-dependent nephrotic syndrome who was treated with rituximab. For 9 months following therapy she had undetectable CD19 cells in the peripheral circulation. She remained in remission during this period even though therapy was reduced to low-dose, alternate day prednisolone only. After 9 months, CD19 cells were once again detectable. Shortly after CD19 cells became detectable again she relapsed. We conclude that B-lymphocytes play a central role in the pathogenesis of idiopathic minimal change nephrotic syndrome (MCNS) and that rituximab may have a useful role in the management of steroid-dependent patients.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Female
  • Humans
  • Infant
  • Nephrosis, Lipoid / drug therapy*
  • Nephrotic Syndrome / drug therapy*
  • Prednisone / therapeutic use*
  • Rituximab
  • Steroids / chemistry*


  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Steroids
  • Rituximab
  • Prednisone